Patient Square Capital LP Invests $15.99 Million in argenex SE $ARGX

Patient Square Capital LP acquired a new stake in argenex SE (NASDAQ:ARGX) during the second quarter, HoldingsChannel reports. The fund acquired 29,000 shares of the company’s stock, valued at approximately $15,985,000. argenex makes up about 5.8% of Patient Square Capital LP’s holdings, making the stock its 3rd largest holding.

Several other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc lifted its stake in shares of argenex by 4.2% in the 2nd quarter. IFP Advisors Inc now owns 666 shares of the company’s stock worth $367,000 after acquiring an additional 27 shares during the period. Keudell Morrison Wealth Management raised its holdings in argenex by 5.5% during the second quarter. Keudell Morrison Wealth Management now owns 534 shares of the company’s stock worth $294,000 after purchasing an additional 28 shares in the last quarter. Central Pacific Bank Trust Division lifted its position in argenex by 2.4% in the second quarter. Central Pacific Bank Trust Division now owns 1,278 shares of the company’s stock valued at $704,000 after purchasing an additional 30 shares during the period. Janney Montgomery Scott LLC lifted its position in argenex by 2.6% in the second quarter. Janney Montgomery Scott LLC now owns 1,171 shares of the company’s stock valued at $645,000 after purchasing an additional 30 shares during the period. Finally, Gilbert & Cook Inc. boosted its holdings in argenex by 2.4% in the 2nd quarter. Gilbert & Cook Inc. now owns 1,345 shares of the company’s stock valued at $741,000 after purchasing an additional 31 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Trading Up 2.4%

Shares of NASDAQ ARGX opened at $929.61 on Tuesday. The company’s 50-day moving average price is $802.57 and its 200 day moving average price is $674.85. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.13. The stock has a market cap of $57.24 billion, a price-to-earnings ratio of 39.91, a PEG ratio of 0.93 and a beta of 0.45.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. As a group, research analysts expect that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ARGX shares. Guggenheim reissued a “buy” rating and set a $1,070.00 target price on shares of argenex in a research note on Thursday, September 18th. Deutsche Bank Aktiengesellschaft cut argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. Wedbush boosted their target price on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research report on Friday. Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Finally, Stifel Nicolaus set a $882.00 price objective on shares of argenex in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $903.78.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.